My relationship to the industry regarding the material to be presented is
as follows.
(Check all applicable items. List the specific relationships at the end.)
There is no industry connection to this material.
I am a paid consultant, or have received honoraria or other
compensation (e.g. travelling costs, speaker's fee) from a corporation
that may be affected by this comment (positively or negatively).
I am (or a member of my family is) a stockholder in a corporation
that may be affected by this comment (positively or negatively).
I receive support from the industry for research related
to the subject of my comment.
No conflict of interest for writing this comment/report in IGR
Ancker, Brandt, Burgoyne, Carassa, Congdon, Foster, Greenfield, Konstas,
Minckler, Palmberg, Ritch, Spaeth, Tomita, Yucel
Disclosed:
Friedman: I am a paid consultant or have received honoraria
or other compensation (e.g. travel, speakerfee) from Pfizer and
Alcon, that may be affected by this comment (positively or negatively)
Heijl: Consultant CZM, and Research and Travel support
Harris: I receive support from industry related to the
subject of my comment. Merck, Alcon and Eulilly have provided study
support for studies investigating ocular blood flow.
Hitchings: paid consultant or have received honoraria;
stockholder. Both may be affected by this comment (positively or
negatively)
Kaufman: I am a paid consultant or have received honoraria
or other compensation (e.g. travel, speaker fee) from a corporation
that may be affected by this comment (positively or negatively).
Paid advisor to Pfizer, Alcon, Allergan and Santen, research and
travel support from all these companies
Khaw: Professor P.T. Khaw has/has had research funding
from Cambridge Antibody Technology for research into Trabio (TGF
beta 2 antibody) Polytherics for research into nanomolecules to
prevent inflammation and scarring, ISIS Pharmaceuticals for research
into antisense molecules, and research funding as an inventor of
the use of matrix metalloproteinase inhibitors to prevent scarring
after surgery
Levin: Dr. Levin is a consultant to Allergan, as well
as other pharmaceutical companies, with respect to neuroprotection
Migdal: I am on the Allergan Glaucoma Advisory Board,
a Merck Editorial Board, and Faculty Member for Alcon, Allergan,
Merck and Pfizer. I currently receive research grants from Cambridge
Antibody Technology (TGF beta study) and Allergan (Memantine)
Nicolela: I am a paid consultant or have received honoraria
or other compensation (e.g. travel, speaker fee) from a corporation
that may be affected by this comment (positively or negatively)
Schuman: Dr. Schuman receives royalties from intellectual
property licensed by Massachusetts Institute of Technology to Carl
Zeiss Meditec.
Shaarawy: I am NOT a paid consultant, but I have received
a travel grant from Pfizer (Healon, Viscocanalostomy) for attending
one congress last year
Wang: I receive support from industry for research related
to the subject of my comment. The specific corporate involvement
with this material is as follows: A multicenter randomize-controlled
trial demonstrated that the Erigeron Breviscapus Hand-Mazz (EBHM)
could improve the visual field of glaucoma eyes significantly compared
with placebo group. Dr Wang Ningli is the chief reseacher in this
trial
Wax: Full time Alcon employee, commentary does not pertain
to a commercial product at this time
Zangwill: receive support from industry for research
related to the subject of my comment. Our research group receives
support in the form of equipment from Zeiss Meditec Inc., Laser
Diagnostic Technologies and Heidelberg Engineering
No information received from:
Sugiyama, Toris and Weinreb
The commentators on Basic Science papers were not asked to disclose.
